Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals

Plus deals involving Lantheus/Life Molecular Imaging, Teva/Klinge/Formycon, X4/Norgine, Biohaven/Merus, Lilly/Mediar and more.

Deal Watch 2021
• Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

In keeping with past tradition, the week of the J.P. Morgan Healthcare Conference in San Francisco saw several dozen biopharma deals, with Johnson & Johnson’s $14.6bn bid for Intra-Cellular leading...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal Watch

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By 

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By 

Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.

More from Conferences

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By 

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By 

The UK giant is forecasting peak sales of $5bn plus

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By 

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.